<DOC>
	<DOCNO>NCT00666692</DOCNO>
	<brief_summary>The primary purpose study examine safety volociximab ( V ) combination standard treatment carboplatin ( C ) , paclitaxel ( P ) , bevacizumab ( B ) subject previously untreated chemotherapy advance stage ( IIIB/IV ) non-squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Phase 1b Study With Volociximab Combination With Carboplatin , Paclitaxel , Bevacizumab First-line , Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Phase 1b , multicenter , open-label , dose-escalation study evaluate safety tolerability volociximab combination C/P + B subject previously untreated Stage IIIB/IV non-squamous NSCLC . Subjects treat C/P + B + volociximab ( V ) combination total 6 cycle ( 3 weeks/cycle ) . Subjects stable disease ( SD ) good per Response Evaluation Criteria Solid Tumors ( RECIST ) 6th cycle combination treatment ( C/P + B + V ) consider treatment maintenance phase B + V dose subject withdrawal treatment . Volociximab administer dos range 10 30 mg/kg every 3 week . Paclitaxel , carboplatin , bevacizumab administer registered dos combination . Follow subject extend 90-day period follow last dose volociximab . End study define 90 day last dose volociximab last subject treat study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Males females least 18 year age . Stage IIIB pleural effusion Stage IV nonsquamous NSCLC . Measurable and/or evaluable disease accord RECIST . No prior chemotherapy , biological therapy immunotherapy Stage IIIB/IV disease . Adjuvant therapy early stage disease must complete &gt; = 6 month prior Cycle 1 , Day 1 study . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =1 . A negative pregnancy test ( serum urine ) woman childbearing potential screening . Male subject female subject childbearing potential must willing practice effective contraception study willing able continue contraception 6 month last dose study drug . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) ( accordance national local subject privacy regulation ) . Exclusion Criteria Histological evidence predominantly squamous cell carcinoma . Known central nervous system ( CNS ) metastases . Known allergy sensitivity murine protein , chimeric antibody component product , Cremophor EL ( polyoxyethylated castor oil ) , cisplatin , platinumcontaining compound . Absolute neutrophil count ( ANC ) &lt; 1500/mm3 , hemoglobin level &lt; 10 g/dL , platelet count &lt; 100,000/mm3 . Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase value .2.5 upper limit normal value ( ULN ) ( &gt; 5 ULN subject liver metastasis ) alkaline phosphatase value &gt; 2.5 ULN ( unless document bone metastases responsible increase alkaline phosphatase ) ; total bilirubin &gt; 1.5 mg/dL , serum creatinine &gt; 1.8 mg/dL . Radiation therapy within 1 month Cycle 1 , Day 1 . Documented symptomatic central nervous system ( CNS ) tumor CNS metastases . History thromboembolic event , include cardiovascular cerebrovascular event ( ie , acute myocardial infarction [ AMI ] , stroke ) within 1 year prior Cycle 1 , Day 1 . History known bleeding disorder coagulation defect . History significant hemoptysis ( ie , &gt; = 1/2 teaspoon red blood per event ) gastrointestinal bleeding within 1 year prior Cycle 1 , Day 1 . Major surgery ( eg , exploratory laparotomy ) within 4 week prior Cycle 1 , Day 1 study . Clinically significant unstable medical condition include , limited , uncontrolled diabetes mellitus require insulin , uncontrolled hypertension , uncontrolled symptomatic orthostatic hypotension . Oxygendependent chronic obstructive pulmonary disease . Known active infection require intravenous ( IV ) antibiotic , antiviral , antifungal , include limited chronic human immunodeficiency virus , hepatitis B , hepatitis C infection . Prior bone marrow stem cell transplant . Regular use aspirin , nonsteroidal antiinflammatory agent , agent know inhibit platelet function . Highdose warfarin heparin use . [ Note : Lowdose warfarin ( 1 mg/day ) lowdose heparin IVcatheter patency , lowmolecular weight heparin prophylaxis allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>carcinoma</keyword>
	<keyword>monoclonal antibody therapy</keyword>
	<keyword>anti-angiogenesis</keyword>
</DOC>